P1197: AXICABTAGENE CILOLEUCEL (AXI-CEL) IN COMBINATION WITH RITUXIMAB FOR THE TREATMENT OF RELAPSED/REFRACTORY (R/R) LARGE B-CELL LYMPHOMA (LBCL): OUTCOMES OF THE PHASE 2 ZUMA-14 STUDY

• P. Strati,
• L. Leslie,
• P. Shiraz,
• E. Budde,
• O. O. Oluwole,
• M. Ulrickson,
• A. Ramakrishnan,
• J. Sun,
• R. Shen,
• J. Kanska,
• P. McCroskery,
• J. Dong,
• M. Schupp,
• H. Xu,
• K. Patel

Affiliations

P. Strati

1 The University of Texas MD Anderson Cancer Center, Houston, TX

L. Leslie

2 John Theurer Cancer Center, Hackensack, NJ

P. Shiraz

3 Stanford University, Stanford, CA

E. Budde

4 City of Hope National Medical Center, Duarte, CA

O. O. Oluwole

5 Vanderbilt University Cancer Center, Nashville, TN

M. Ulrickson

6 Banner MD Anderson Cancer Center, Gilbert, Arizona

A. Ramakrishnan

7 Texas Transplant Physician Group, Austin, TX

J. Sun

8 Kite, a Gilead Company, Santa Monica, CA

R. Shen

8 Kite, a Gilead Company, Santa Monica, CA

J. Kanska

8 Kite, a Gilead Company, Santa Monica, CA

P. McCroskery

8 Kite, a Gilead Company, Santa Monica, CA

J. Dong

8 Kite, a Gilead Company, Santa Monica, CA

M. Schupp

8 Kite, a Gilead Company, Santa Monica, CA

H. Xu

8 Kite, a Gilead Company, Santa Monica, CA

K. Patel

9 Swedish Cancer Institute, Seattle, WA, United States of America